Search companies or stocks...
Xenon Pharmaceuticals Inc. (XENE) intrinsic value snapshot: our valuation models currently suggest the stock is overvalued, with an estimated 2279.3% downside relative to fair value at a market price of $68.92. The dollar intrinsic value (fair value) for Xenon Pharmaceuticals Inc. is derived from DCF, P/E Multiple, and P/S Multiple models—available with Tickerplace Pro for investors comparing market price to modeled fair value.
Intrinsic Value (Fair Value): Unlock fair value
Downside: -2279.3%
Margin of Safety: Unlock fair value
Current Price: $68.92
Valuation: Overvalued
Confidence: 9.5/10
How we calculate fair value: We combine DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models to estimate intrinsic value. This figure is for information only - not investment advice - and assumptions may not reflect actual market conditions. We encourage doing your own research or speaking with a financial advisor before making investment decisions.
Search our company database (same as the site header), pick a match, or type a ticker to open its intrinsic value analysis.
Based on our intrinsic value models, Xenon Pharmaceuticals Inc. (XENE) currently looks overvalued with an estimated 2279.26% downside relative to fair value at $68.92. Sign in to Tickerplace Pro to view the full dollar fair value estimate and margin of safety.
Xenon Pharmaceuticals Inc. (XENE) fair value vs market price: our valuation models suggest overvalued positioning with an estimated 2279.3% downside relative to intrinsic value at a market price of $68.92. The dollar fair value for Xenon Pharmaceuticals Inc. is calculated from DCF, P/E Multiple, and P/S Multiple models—available with Tickerplace Pro for a full market-price-to-fair-value breakdown and margin of safety.
Our models calculate the intrinsic value of Xenon Pharmaceuticals Inc. (XENE) using DCF, P/E Multiple, and P/S Multiple approaches based on projected cash flows, growth rate, and discount rate. Sign in to Tickerplace Pro to view the full dollar estimate.
Based on our 2026 valuation models, XENE appears overvalued at its current price of $68.92. Our model suggests the stock may be overvalued by 2279.3%.
Tickerplace calculates XENE's intrinsic value using Discounted Cash Flow (DCF), P/E Multiple, and P/S Multiple models. We project future cash flows, apply a discount rate that reflects investment risk, and compare the resulting fair value estimate to the current market price.
Peers for XENE: open their intrinsic value pages.
